Your address will show here +12 34 56 78
Press & Media

Last November FLUOPTICS receives the market authorization from FDA for FLUOBEAM® to detect parathyroid tissue in real time during surgery.
It is a recognition of the performance of the FLUOBEAM® and for the development of fluorescence imaging.
Today, we are highlighted in the Presences revue of the Grenoble CCI for this market authorization.
For more information, please click on the link Présences_CCI de Grenoble.

0

Press & Media

FLUOPTICS receives the market authorization from FDA for FLUOBEAM® to detect parathyroid tissue in real time during surgery. The FLUOBEAM® Imaging System becomes the first and unique system certified for this indication.
The FLUOBEAM® provides, earlier, real-time location of parathyroid tissue during surgical procedures such as thyroidectomy (surgery to remove all or part of the thyroid) and parathyroidectomy (surgery to remove one or more parathyroid glands). The early detection of theses glands allows reduces postoperative hypocalcemia.
It is a recognition of the performance of the FLUOBEAM® and for the development of fluorescence imaging.

0